Elevated serum levels of soluble vascular cell adhesion molecule‐1 (sVCAM‐1) closely reflect tumour burden in chronic B‐lymphocytic leukaemia

The present study is the first to report elevated serum levels of soluble (s)VCAM‐1 in B‐cell chronic lymphocytic leukaemia (B‐CLL). A large cohort of 106 untreated patients was studied. sVCAM‐1 was compared to known prognostic serum markers (soluble (s)ICAM‐1; lactate dehydrogenase, LDH; sCD23; thymidine kinase, TK; β2microglobulin, β2m). The serum levels of sVCAM‐1 reflected tumour burden as expressed by Binet/Rai stages more closely than any other marker. sVCAM‐1 also reflected the kinetics of the disease as revealed by lymphocyte doubling time. sVCAM‐1 was the only one of the studied markers which showed elevated levels in smouldering disease compared to controls. sVCAM‐1, sICAM‐1 and sCD23 (but not LDH, TK, β2m) separated smouldering from non‐smouldering B‐CLL. Only sICAM‐1, sCD23 and TK added independent prognostic information for survival to that of stage and lymphocyte doubling time.

[1]  K. Nilsson,et al.  Beta 2-microglobulin in chronic lymphocytic leukaemia. , 2009, Scandinavian journal of haematology.

[2]  T. Tötterman,et al.  Soluble vascular cell adhesion molecule‐1 (sVCAM‐1) is an independent prognostic marker in Hodgkin's disease , 1998, British journal of haematology.

[3]  D. Catovsky,et al.  Adhesion receptors on peripheral blood leukemic B cells. A comparative study on B cell chronic lymphocytic leukemia and related lymphoma/leukemias , 1997, Leukemia.

[4]  M. Hallek,et al.  Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. , 1996, Leukemia & lymphoma.

[5]  J. Burthem,et al.  Integrin function in chronic lymphocytic leukemia. , 1996, Blood.

[6]  Michael Loran Dustin,et al.  Characterization of intercellular adhesion molecule-1 ectodomain (sICAM-1) as an inhibitor of lymphocyte function-associated molecule-1 interaction with ICAM-1. , 1995, Journal of immunology.

[7]  A. Koch,et al.  Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1 , 1995, Nature.

[8]  S. Molica,et al.  Expression on leukemic cells and serum circulating levels of intercellular adhesion molecule-1 (ICAM-1) in B-cell chronic lymphocytic leukemia: implications for prognosis. , 1995, Leukemia research.

[9]  V. Bažil.  Physiological enzymatic cleavage of leukocyte membrane molecules. , 1995, Immunology today.

[10]  Y. Ning,et al.  The vascular cell adhesion molecule (VCAM‐1) is expressed on a subset of lymphoid and myeloid leukaemias , 1995, British journal of haematology.

[11]  R. Coffman,et al.  IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. , 1995, Journal of immunology.

[12]  T. Tötterman,et al.  Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers [see comments] , 1994 .

[13]  C. Gasche,et al.  Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  T. Carlos,et al.  Leukocyte-endothelial adhesion molecules. , 1994, Blood.

[15]  L. Florensa,et al.  Expression of lymphocyte function-associated antigen (LFA)-1 in B-cell chronic lymphocytic leukemia. , 1994, Leukemia & lymphoma.

[16]  Manuel E. Patarroyo,et al.  Expression of Adhesion Molecules CD 11/CD 18 (Leu-CAMs, β2-Integrins), CD54 (ICAM-1) and CD58 (LFA-3) in B -Chronic Lymphocytic Leukemia , 1994 .

[17]  J. Becker,et al.  Soluble intercellular adhesion molecule-1 inhibits MHC-restricted specific T cell/tumor interaction. , 1993, Journal of Immunology.

[18]  T. Tötterman,et al.  Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells. , 1993, Blood.

[19]  O. Söderberg,et al.  Interleukin‐4 (IL‐4) Enhances Homotypic Adhesion of Activated B‐Chronic Lymphocytic Leukaemia (B‐CLL) Cells via a Selective Up‐Regulation of CD54 , 1993, Scandinavian journal of immunology.

[20]  F. Takei,et al.  Inhibition of cell adhesion by microspheres coated with recombinant soluble intercellular adhesion molecule-1. , 1993, Journal of immunology.

[21]  H. Juneja,et al.  Vascular cell adhesion molecule-1 and VLA-4 are obligatory adhesion proteins in the heterotypic adherence between human leukemia/lymphoma cells and marrow stromal cells. , 1993, Experimental hematology.

[22]  J. Neefjes,et al.  E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. , 1992, Immunology.

[23]  C. Abboud,et al.  Inhibition of human bone marrow lymphoid progenitor colonies by antibodies to VLA integrins. , 1992, Journal of immunology.

[24]  M. Maio,et al.  Expression and functional role of CD54/Intercellular Adhesion Molecule-1 (ICAM-1) on human blood cells. , 1992, Leukemia & lymphoma.

[25]  P. Kincade.  Cell interaction molecules and cytokines which participate in B lymphopoiesis. , 1992, Bailliere's clinical haematology.

[26]  E. Montserrat,et al.  5th International Workshop on Chronic Lymphocytic Leukemia. , 1992, Leukemia research.

[27]  H. Hojo,et al.  Expression of leukocyte adhesion molecules (ICAM‐1/LFA‐1) related to clinical behaviour in B cell lymphomas , 1992, Hematological oncology.

[28]  K. Koretz,et al.  Adhesion molecules VLA-1 to VLA-6 define discrete stages of peripheral B lymphocyte development and characterize different types of B cell neoplasia. , 1992, Leukemia.

[29]  J. Becker,et al.  Shedding of ICAM-1 from human melanoma cell lines induced by IFN-gamma and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. , 1991, Journal of immunology.

[30]  C. Abboud,et al.  Vascular cell adhesion molecule-1 and the integrin VLA-4 mediate adhesion of human B cell precursors to cultured bone marrow adherent cells. , 1991, The Journal of clinical investigation.

[31]  T. Carlos,et al.  Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. , 1990, Blood.

[32]  F. Ferrara,et al.  Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders. , 1990, Blood.

[33]  M. Thornhill,et al.  IL-4 regulates endothelial cell activation by IL-1, tumor necrosis factor, or IFN-gamma. , 1990, Journal of immunology.

[34]  R. Larson,et al.  Structure and Function of Leukocyte Integrins , 1990, Immunological reviews.

[35]  R. Rothlein,et al.  Induction of intercellular adhesion molecule 1 on primary and continuous cell lines by pro-inflammatory cytokines. Regulation by pharmacologic agents and neutralizing antibodies. , 1988, Journal of immunology.

[36]  Ciril Rozman,et al.  Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance , 1986, British journal of haematology.

[37]  B Simonsson,et al.  Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia , 1984, Cancer.

[38]  Mark J. Thomas,et al.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.

[39]  F. Schriever,et al.  Differential adhesion pattern of B cell chronic lymphocytic leukemia cells , 1998, Leukemia.

[40]  A. Jewell,et al.  Regulation and function of adhesion molecules in B-cell chronic lymphocytic leukaemia. , 1997, Acta haematologica.

[41]  S. Molica,et al.  Clinico-prognostic implications of increased levels of soluble CD54 in the serum of B-cell chronic lymphocytic leukemia patients. Results of a multivariate survival analysis. , 1997, Haematologica.

[42]  E. González-Barca,et al.  Expression of adhesion molecules in 113 patients with B-cell chronic lymphocytic leukemia: relationship with clinico-prognostic features. , 1997, Leukemia research.

[43]  T. Tötterman,et al.  Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers. , 1994, Blood.

[44]  E. Wayner,et al.  Regulation of human B-cell precursor adhesion to bone marrow stromal cells by cytokines that exert opposing effects on the expression of vascular cell adhesion molecule-1 (VCAM-1). , 1993, Blood.

[45]  G. Rice,et al.  Vascular and nonvascular expression of INCAM-110. A target for mononuclear leukocyte adhesion in normal and inflamed human tissues. , 1991, The American journal of pathology.

[46]  J. Johnson.  The role of ICAM-1 in tumor development. , 1991, Chemical immunology.

[47]  L. Lagneaux,et al.  Elevation of IgE-binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia. , 1988, Blood.

[48]  D C Case,et al.  Clinical staging of chronic lymphocytic leukemia. , 1977, The Journal of the Maine Medical Association.